Papilloedema secondary to oligodendroglioma

References

• The committee of Brain Registry of Japan. Report of Brain Tumor Registry of Japan (2001‐2004). Neurol Med Chir (Tokyo) 2014; 54 (Suppl): PS9–PS102.
   Google Scholar
• Makuria AT, Henderson FC, Rushing EJ, Hartmann DP, Azumi N, Ozdemirli M. Oligodendroglioma with neurocytic differentiation versus atypical extraventricular neurocytoma: a case report of unusual pathologic findings of a spinal cord tumor. J Neurooncol 2007; 82: 199–205.
   Web of Science ®Google Scholar
• Mut M, Guler‐tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE. Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma. Clin Neuropathol 2005; 24: 225–229.
   Web of Science ®Google Scholar
• Okada M, Yano H, Hirose Y et al. Olig2 is useful in the differential diagnosis of oligodendrogliomas and extraventricular neurocytomas. Brain Tumor Pathol 2011; 28: 157–161.
   Web of Science ®Google Scholar
• Zada G, Mcnatt SA, Gonzalez‐gomez I, Mccomb JG. Anaplastic intraventricular oligodendroglioma: case report and review of the literature. Surg Neurol 2009; 71: 693–700.
   Google Scholar
• Matsumoto H, Yasuhisa Y. Primary intraventricular oligodendroglioma: A case report of the usefulness of Olig2 immunohistochemistry for diagnosis. Neuropathology 2015; 35: 553–560.
   Web of Science ®Google Scholar
• Raciti‐daurio C, Caruso J. Oligodendroglioma‐a case presentation. Optom Vis Sci 1990; 67: 56–58.
   Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Fulop J et al. CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2008‐2012. Neuro Oncol 2015. iv1–iv62.
   Google Scholar
• Kleihues P, Cavenee W. Tumours of the nervous system: World Health Organization classification of tumours. Lyon, France: IARC Press, 2000.
   Google Scholar
• Van den bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol 2008; 66: 262–272.
   PubMed Web of Science ®Google Scholar
• Marks ES, Adamczyk DT, Thomann KH. Primary Eyecare in Systemic Disease. Norwalk: Appleton & Lange, 1995. p 67–84.
   Google Scholar
• Rubin P. Clinical Oncology for Medical Students and Physicians: A Multidisciplinary Approach. 5th ed. Rochester, New York: American Cancer Society, 1978. p 181–184.
   Google Scholar
• Chin HW, Hazel JJ, Kim TH, Webster JH. Oligodendrogliomas: a clinical study of cerebral oligondendrogliomas. Cancer 1980; 45: 1458–1466.
   PubMed Web of Science ®Google Scholar
• Thurtell MJ, Tomsak RL, Daroff RB. Neuro‐ophthalmology, New York, New York: Oxford University Press, 2012.
   Google Scholar
• Karnofsky D, Abelman W, Craver L, Burchenal J. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634–656.
   Web of Science ®Google Scholar
• Whitely W, Al shahi R, Warlow CP, Zeidler M, Lueck CJ. CSF opening pressure: reference interval and the effect of the body mass index. Neurology 2006; 67: 1690–1691.
   Web of Science ®Google Scholar
• Megyesi JF, Kachur E, Lee DH et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004; 10: 4303–4306.
   PubMed Web of Science ®Google Scholar
• Shaw EG, Scheithauer BW, O'fallon JR. Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 1997; 31: 273–278.
   PubMed Web of Science ®Google Scholar
• Celli P, Nofrone I, Palma L, Cantore G, Fortuna A. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994; 35: 1018–1034.
   PubMed Web of Science ®Google Scholar
• Schiffer D, Dutto A, Cavalla P et al. Prognostic factors in oligodendroglioma. Can J Neurol Sci 1997; 24: 313–319.
   Web of Science ®Google Scholar
• Daumas‐duport C, Tucker, ML, Kolles H et al. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol 1997; 34: 61–78.
   PubMed Web of Science ®Google Scholar
• Kros JM, Pieterman H, van Eden CG, Avezaat CJ. Oligodendroglioma: the Rotterdam‐Dijkzigt experience. Neurosurgery 1994; 34: 959–966.
   PubMed Web of Science ®Google Scholar
• Pignatti F, van den Bent M, Curran D et al. Prognostic factors for survival in adult patients with cerebral low‐grade glioma. J Clin Oncol 2002; 20: 2076–2084.
   PubMed Web of Science ®Google Scholar
• Cairncross G, Wang M, Shaw E et al. Phase III trial of chemotherapy for anaplastic oligodendroglioma: long term results of RTOG 9402. J Clin Oncol 2013; 31: 337–343.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Taphoorn MJ et al. Adjuvant procarbazine, lomustine, vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long term follow‐up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344–350.
   PubMed Web of Science ®Google Scholar
• Stevens GHJ. Brain tumors: meningiomas and gliomas. Available at: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology‐oncology/brain‐tumors.htm. [Accessed December 13, 2015].
   Google Scholar
• Wall M. Idiopathic intracranial hypertension. Neurol Clin 2010; 28: 593–617.
   PubMed Web of Science ®Google Scholar
• Griffin CA, Burger P, Morsberger L et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006; 65: 988–994.
   PubMed Web of Science ®Google Scholar
• Jenkins RB, Blair H, Ballman KV et al. At (1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66: 9852–9861.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765–773.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Agrawal N, Jiao Y et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333: 1453–1455.
   PubMed Web of Science ®Google Scholar
• Yip S, Butterfield YS, Morozova O et al. Concurrent CIC mutations, IDH mutations and 1P/19q loss distinguish oligondendroglioma from other cancers. J Pathol 2012; 226: 7–16.
   PubMed Web of Science ®Google Scholar
• Kulkami K, Pasol J, Rosa PR, Lam BL. Differentiating mild papilledema and buried optic nerve head drusen using spectral domain optical coherence tomography. Ophthalmology 2014; 121: 959–963.
   Web of Science ®Google Scholar
• Tamhankar MA. The papilledema dilemma. Ophthalmol Manag 2015;19: 34–64.
   Google Scholar
• Frisen L. Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Pscyhiatr 1982; 45: 13–18.
   PubMed Web of Science ®Google Scholar
• Galetta S, Byrne SF, Smith JL. Echographic correlation of optic nerve sheath size and cerebrospinal fluid pressure. J Clin Neuro‐ophthalmol 1989; 9: 79–82.
   PubMedGoogle Scholar
• Friedman DI, Mcdermott MP, Kieburtz K et al. The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT): design considerations and methods. J Neuroophthalmol 2014; 34: 107–117.
   PubMed Web of Science ®Google Scholar
• Shikha TB, Kuppuswamy PM. Optical coherence tomography in papilledema and pseudopapilledema with and without optic nerve head drusen. Indian J Ophthalmol 2014; 62: 1146–1151.
   Web of Science ®Google Scholar
• Bassi ST, Mohana KP. Optical coherence tomography in papilledema and pseudopapilledema with and without optic nerve head drusen. Indian J Ophthalmol 2014; 62: 1146–1151.
   PubMed Web of Science ®Google Scholar
• Johnson LN, Diehl ML, Hamm CW, Sommerville DN, Petroski GF. Differentiating optic disc edema from optic nerve head drusen on optical coherence tomography. Arch Ophthalmol 2009; 127: 45–49.
   PubMedGoogle Scholar
• Lee KM, Woo SJ, Hwang JM. Differentiation of optic nerve head drusen and optic disc edema with spectral‐domain optical coherence tomography. Ophthalmology 2011; 118: 971–977.
   Web of Science ®Google Scholar
• Sarac O, Tasci YY, Gurdal C, Can I. Differentiation of optic disc edema from optic nerve head drusen with spectral‐domain optical coherence tomography. J Neuroophthalmol 2012; 32: 207–211.
   Web of Science ®Google Scholar
• Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1886–1893.
   PubMed Web of Science ®Google Scholar